On Friday 27th November 2020, Pharmac released public consultation on a proposal to widen access to funded multiple sclerosis treatments and transition access from the Multiple Sclerosis Treatment Assessment Committee (MSTAC) Panel to a standard Special Authority.
Consultation closes 4pm Friday 18 December and Multiple Sclerosis New Zealand want to hear more from YOU about how YOU see these changes impacting YOUR life.
We would like to invite ALL those interested in hearing more about what the changes to the criteria for MS treatments will mean.
We will be joined by two leading experts in Multiple Sclerosis, Dr John Mottershead, Specialist Neurologist at Southern DHB, and Dr Deborah Mason, Specialist Neurologist at Canterbury DHB. As well as informing about the changes and what they will mean for both patients and clinicians, there will be a 15-minute Q&A session with our experts. Questions can be submitted prior to the event by emailing email@example.com.
MS Treatments Proposal – Public Consultation Meeting
Date: Friday 11th December 2020
Time: 12pm – 12.35pm
Location: Zoom (link will be sent out at 10am on the day of the event)
A recording of the meeting will be made available on our website after the event. You can select ‘Post Event Link Only’ to be sent the recording directly.
Please follow this link to read the proposal and recommended changes to the Special Authority for access.
You can also read MSNZs initial response to the announcement.
Your Feedback is Important
Pharmac want and need to hear about how these changes will impact the lives of those living with MS. Feedback on the public consultation can be emailed to firstname.lastname@example.org.
Alternatively, Multiple Sclerosis NZ are seeking testimonials from people who will be impacted by the proposed changes to include in our submission. If you would like to be included in this please send your testimonial to email@example.com. Thank you.